Human astrocytomas co-expressing Fas and Fas ligand also produce TGFβ2 and Bcl-2

Journal of Neuro-Oncology

Volumn 44, Issue 3, 1999, Pages 205-212

  Frankel, Bruce ^a   Longo, Sharon L ^a   Ryken, Timothy C ^b  

^a SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^b UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

B cell lymphoma leukemia 2 (Bcl 2); Fas; Fas ligand; Human astrocytomas; Transforming growth factor 2(TGF 2)

Indexed keywords

FAS ANTIGEN; FAS LIGAND; TRANSFORMING GROWTH FACTOR BETA2;

APOPTOSIS; ARTICLE; ASTROCYTOMA; B CELL LYMPHOMA; CANCER GRADING; CANCER SURVIVAL; CONTROLLED STUDY; EXPRESSION VECTOR; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; IMMUNOREACTIVITY; IN VIVO STUDY; MAJOR CLINICAL STUDY; PROTEIN EXPRESSION; TUMOR GROWTH;

ANTIGENS, CD95; ASTROCYTOMA; FAS LIGAND PROTEIN; GLIOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; MEMBRANE GLYCOPROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; TRANSFORMING GROWTH FACTOR BETA;

EID: 0033500334     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006311231189     Document Type: Article

References (42)

1. Jaeckle K: Immunotherapy of malignant gliomas. Semin Oncol 21: 249-259, 1994
2. Rossi ML, Hughes JT, Esiri MM, Coakham HB, Brownell DB: Immunohistological study of mononuclear cell infiltrate in malignant gliomas. Acta Neuropathol (Berl) 74: 269-277, 1987
3. Cheng J, Zhou T, Liu C, Shapiro JP, Brauer MJ, Kiefer MC, Barr PJ, Mountz JD: Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 263: 1759-1762, 1994
4. Weller M, Malipiero U, Rensing-Ehl A, Barr PJ, Fontana A: Fas/Apo-1 gene transfer for human malignant glioma. Cancer Res 55: 2936-2944, 1995
5. Midis GP, Shen Y, Owen-Schaub LB: Elevated soluble Fas (sFas) levels in nonhematopoietic human malignancy. Cancer Res 56: 3870-3874, 1996
6. Saas P, Walker PR, Hahne M, Quiquerez AL, Schnuriger V, Perrin G, French L, Van Meir EG, De Tribolet N, Tschopp J, Dietrich PY: Fas ligand expression by astrocytoma in vivo: Maintaining immune privilege in the brain? J Clin Invest 99: 1173-1178, 1997
7. Walker PR, Saas P, Dietrich PY: Role of Fas ligand (CD95L) in immune escape: The tumor cell strikes back. J Immunol. 158: 4521-4524, 1997
8. Bodmer S, Strommer K, Frei K, Siepl C, De Tribolet N, Held I, Fontana A: Immunosuppression and transforming growth factor-β in glioblastoma: Preferential production of transforming growth factor-β2. J Immunol 143: 3222-3229, 1989
9. Weller M, Malipiero U, Aguzzi A, Reed JC, Fontana A: Protooncogene bcl-2 gene transfer abrogates Fas/APO-1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation. J Clin Invest 95: 2633-2643, 1995
10. Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima SI, Sameshima M, Hase A, Seto Y, Nagata S: The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 66: 233-243, 1991
11. Suda T, Takahashi T, Golstein P, Nagata S: Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 75: 1169-1178, 1993
12. Enari M, Hug H, Nagata S: Involvement of an ICE-like protease in Fas-mediated apoptosis. Nature 375: 78-81, 1995
13. Leithäuser F, Dhein J, Mechtersheimer G, Koretz K, Brüderlein S, Henne C, Schmidt A, Debatin KM, Krammer PH, Möller P: Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab Invest 69: 415-429, 1993
14. Tachibana O, Nakazawa H, Lampe J, Watanabe K, Kleihues P, Ohgaki H: Expression of Fas/APO-1 during the progression of astrocytomas. Cancer Res 55: 5528-5530, 1995
15. Tachibana O, Lampe J, Kleihues P, Ohgaki H: Preferential expression of Fas/APO1 (CD95) and apoptotic cell death in perinecrotic cells of glioblastoma multiforme. Acta Neuropathol 92: 431-434, 1996
16. Tanaka M, Suda T, Takahashi T, Nagata S: Expression of the functional soluble form of human Fas ligand in activated lymphocytes. EMBO J 14: 1129-1135, 1995
17. Hahne M, Renno T, Schroeter M, Irmler M, French L, Bornand T, MacDonald HR, Tschopp J: Activated B cells express functional Fas ligand. Eur J Immunol 26: 721-724, 1996
18. Arase H, Arase N, Takashi S: Fas-mediated cytotoxicity by freshly isolated natural killer cells. J Exp Med 181: 1235-1238, 1995
19. Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA: Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 270: 1189-1192, 1995
20. Gratas C, Tohma Y, Van Meir EG, Klein M, Tenan M, Ishii N, Tachibana O, Kleihues P, Ohgaki H: Fas ligand expression in glioblastoma cell lines and primary astrocytic brain tumors. Brain Pathol 7: 863-869, 1997
21. Husain N, Chiocca EA, Rainov N, Louis DN, Zervas NT: Co-expression of Fas and Fas ligand in malignant glial tumors and cell lines. Acta Neuropathol 95: 287-290, 1998
22. Nagata S: Fas ligand and immune evasion. Nature Med 2: 1306-1307, 1996
23. Kägi D, Vignaux F, Ledermann B, Bürki K, Depraetere V, Nagata S, Hengartner H, Golstein P: Fas and perform pathways as major mechanisms of T cell-mediated cytotoxicity. Science 265: 528-530, 1994
24. Weller M, Frei K, Groscurth P, Krammer PH, Yonekawa Y, Fontana A: Anti-fas/APO1 antibody-mediated apoptosis of cultured human glioma cells: Induction and modulation of sensitivity by cytokines. J Clin Invest 94: 954-964, 1994
25. Toda K, Shiraishi T, Hirotsu T, Fukuyama K, Mineta T, Kawaguchi S, Tabuchi K: The cytocidal activity of OK-432-activated mononuclear cells against human glioma cells is partly mediated through the Fas ligand/Fas system. Jpn J Cancer Res 87: 972-976, 1996
26. Schiffer D, Cavalla P, Migheli A, Chiò A, Giordana MT, Marino S, Attanasio A: Apoptosis and cell proliferation in human neuroepithelial tumors. Neurosci Lett 195: 81-84, 1995
27. Massagué J: TheTGF-β family of growth and differentiation factors. Cell 49: 437-438, 1987
28. Kehrl JH, Wakefield LM, Roberts AB, Jakowlew S, Alvarez-Mon M, Derynck R, Sporn MB, Fauci AS: Production of transforming growth factor βby human T lymphocytes and its potential role in the regulation of T cell growth. J Exp Med 163: 1037-1050, 1986
29. Kehrl JH, Roberts AB, Wakefield LM, Jakowlew S, Sporn MB, Fauci AS: Transforming growth factor βis an important immunomodulatory protein for human B lymphocytes. J Immunol 137: 3855-3860, 1986
30. Rook AH, Kehrl JH, Wakefield LM, Roberts AB, Sporn MB, Burlington DB, Lane HC, Fauci AS: Effects of transforming growth factor β on the functions of natural killer cells: Depressed cytolytic activity and blunting of interferon responsiveness. J Immunol 136: 3916-3920, 1986
31. Kuppner MC, Hamou MF, Bodmer S, Fontana A, De Tribolet N: The glioblastoma-derived T-cell suppressor factor/transforming growth factor beta, inhibits the generation of lymphokine-activated killer (LAK) cells. Int J Cancer 42: 562-567, 1988
32. Espevik T, Figari IS, Shalaby MR, Lackides GA, Lewis GD, Shepard HM, Palladino MA: Inhibition of cytokine production by Cyclosporin A and transforming growth factor β. J Exp Med 166: 571-576, 1987
33. Zuber P, Kuppner MC, De Tribolet N: Transforming growth factor-β2 down-regulates HLA-DR antigen expression on human malignant glioma cells. Eur J Immunol 18: 1623-1626, 1988
34. Yamada N, Kato M, Yamashita H, Nistér M, Miyazono K: Enhanced expression of transforming growth factor-β and its type-I and type-II receptors in human glioblastoma. Int J Cancer 62: 386-392, 1995
35. Tsujimoto Y, Cossman J, Jaffe E, Croce CM: Involvement of the bcl-2 gene in human follicular lymphoma. Science 228: 1440-1443, 1985
36. Hockenbery DM, Zutter M, Hickey W, Nahm M, Korsmeyer SJ: Bcl2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci 88: 6961-6965, 1991
37. Krajewski S, Krajewska M, Ehrmann J, Sikorska M, Lach B, Chatten J, Reed JC: Immunohistochemical analysis of Bcl-2, Bcl-x, Mcl-1, and Bax in tumors of central and peripheral nervous system origin. Am J Pathol 150: 805-814, 1997
38. Ellison DW, Steart PV, Gatter KC, Weller RO: Apoptosis in cerebral astrocytic tumors and its relationship to expression of the bcl-2 and p53 proteins. Neuropathol Appl Neurobiol 21: 352-361, 1995
39. Nakasu S, Nakasu Y, Nioka H, Nakajima M, Hanada J: bcl-2 protein expression in tumors of the central nervous system. Acta Neuropathol 88: 520-526, 1994
40. Krishna M, Smith TW, Recht LD: Expression of bcl-2 in reactive and neoplastic astrocytes: Lack of correlation with presence or degree of malignancy. J Neurosurg 83: 1017-1022, 1995
41. Newcomb EW, Bhalla SK, Parrish CL, Hayes RL, Cohen H, Miller DC: bcl-2 protein expression in astrocytomas in relation to patient survival and p53 gene status. Acta Neuropathol 94: 369-375, 1997
42. Maxwell M, Galanopoulos T, Neville-Golden J, Antoniades HN: Effect of the expression of transforming growth factor-β2 in primary human glioblastomas on immunosuppression and loss of immune surveillance. J Neurosurg 76: 799-804, 1992